Science · Biotechnology
are cell-free systems scalable for decentralized biomanufacturing?
Cell-free approaches remove living cells from the production equation, using extracted molecular machinery to synthesize proteins and other biomolecules. Cell-free systems are inherently modular and can be configured for rapid
how can directed evolution accelerate enzyme optimization for industrial biocatalysis?
Directed evolution mimics natural selection in the laboratory to produce enzymes with improved activity, stability, or selectivity for industrial processes. Frances Arnold California Institute of Technology pioneered iterative rounds of
how can synthetic biology reduce reliance on petrochemicals through microbial biomanufacturing?
Synthetic biology redirects chemical production from petroleum to living cells by redesigning microbial metabolism to make valuable molecules from renewable feedstocks. Jay Keasling at the University of California, Berkeley demonstrated
what strategies minimize horizontal gene transfer risks in engineered microbes?
Horizontal gene transfer between engineered microorganisms and environmental microbes poses ecological, public health, and regulatory challenges. Causes include exchange of mobile genetic elements such as plasmids, bacteriophages that mediate transduction,
how can biosafety standards evolve for engineered organism environmental release?
Evolving biosafety standards for environmental release of engineered organisms requires evidence-driven frameworks that integrate science, social context, and governance. Advances in gene editing and synthetic biology increase both capabilities and
how can metabolic engineering increase microbial production of biodegradable plastics?
Microbial production of biodegradable plastics such as polyhydroxyalkanoates relies on converting renewable carbon into polymer precursors inside living cells. Metabolic engineering increases yields and lowers costs by redesigning cellular pathways,
how can phage therapy be standardized for clinical antimicrobial use?
Phage therapy must move from artisanal, case-by-case use to reproducible clinical practice by aligning biological characterization, manufacturing controls, and regulatory frameworks with established drug standards. Evidence from long-standing centers and
what innovations enable scalable bioprinting of vascularized human tissues?
Advanced bioprinting of perfusable human tissues depends on coordinated innovations across materials science, engineering, and cell biology. Clinical demand for transplantable tissues and drug-testing platforms drives research toward solutions that
how will cellular agriculture scale to replace animal-derived proteins?
Cellular agriculture aims to scale by solving engineering, economic, and social problems so that cell-derived proteins can compete with conventional animal agriculture. Early demonstrations and environmental assessments show promise, but
how can synthetic organoids model human disease progression and drug response?
Synthetic organoids—three-dimensional cell cultures that self-organize into miniaturized tissue-like structures—offer a tractable platform to model human disease progression and predict drug response by preserving patient-specific genetics and cell interactions. Hans